CRP

News CRP

• Vasogen Announces Results from Phase III SIMPADICO Trial in Peripheral Arterial Disease

  Vasogen Inc. announced the results from the 553-patient phase III SIMPADICO trial of its Celacade(TM) technology (Celacade) in peripheral arterial disease (PAD). While the SIMPADICO study did not reach the primary endpoint of change in maximal treadmill walking distance, Celacade significantly reduc more

• Xantos Biomedicine AG and Cryptome Pharmaceuticals Ltd collaborate to validate cancer lead

  Xantos Biomedicine AG announced that it has signed a collaboration agreement with Cryptome Pharmaceuticals Ltd, Melbourne, Australia. Xantos has used XantoScreen(TM) technology to discover novel proteins that mediate proliferation of vascular endothelial cells, which potentially play a role in the f more

• deCODE Paper Describes Efficacy of DG031 in Controlling Key Indicators of Risk for Heart Attack

  deCODE genetics announced the publication of a landmark article by a team of its scientists presenting the results of Phase II clinical studies of DG031, the company's lead compound being developed for the prevention of myocardial infarction, or heart attack. The results demonstrate that DG031 works more

White papers CRP

• Interference and HAMA problems
  

  Immunoassays are bioanalytical methods based on antibodies. These include ELISA, EIA, RIA, Western blotting, protein arrays, lateral flow assays (immuno-chromatography), immunohistochemistry or immuno-PCR. Antibodies detect the substances (analytes) in immunoassays. This detection is always highly specific and only the analytes are detected and bound. This is the theory! Practically any antibody not only binds its analyte. It also binds several other substances, but with very different affinities. more

Publications CRP

• Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: evidence in patients with acute myocardial infarction

  Publication date: Available online 9 May 2013 Source:European Journal of Pharmaceutical Sciences Author(s): Beatriz Paradela-Dobarro , Sergio Raposeiras-Roubín , Bruno K. Rodiño-Janeiro , Lilian Grigorian-Shamagian , José M. García-Acuña , Pablo Aguiar-Souto , Michel Jacquet-Hervet , Ma more

• Relationships between biomarkers of inflammation, ovarian steroids, and age at menarche in a rural polish sample

  Objectives To test the hypothesis that life history trade‐offs between maintenance and reproductive effort would be evident through inverse associations between levels of a biomarker of inflammation [C‐reactive protein (CRP)], and ovarian hormones. Associations between CRP and age at menarche we more

• A dual regulatory role of cyclic adenosine monophosphate receptor protein in various virulence traits of Vibrio vulnificus

  Abstract Vibrio vulnificus causes fatal septicemia in susceptible subjects after the ingestion of raw seafood. In the present study, the roles of cyclic adenosine monophosphate (cAMP) receptor protein (CRP) in V. vulnificus pathogenesis were investigated. A mutation in the V. vulnificus crp gen more

Market studies CRP

• HTL-STREFA S.A. (HTL) - Financial and Strategic SWOT Analysis Review

  HTL-STREFA S.A (HTL) is engaged in the development, manufacture and marketing of medical disposable products for the healthcare markets. The company develops capillary blood collection devices, which are used in diagnostic purposes such as monitoring blood glucose, cholesterol, hemoglobin, CRP-tests more

• Suven Life Sciences Ltd. (530239) - Financial and Strategic SWOT Analysis Review

  Suven Life Sciences Ltd. (Suven) is a biotechnology company engaged in the business of design, manufacture and supply of bulk actives, drug intermediates and fine chemicals, catering to the needs of life science industry. It operates in three segments namely Manufacturing (CRAMS), that includes inte more

• Suven Life Sciences Ltd. (SUVEN) - Financial and Strategic SWOT Analysis Review

  Suven Life Sciences Ltd. (Suven) is a biotechnology company engaged in the business of design, manufacture and supply of bulk actives, drug intermediates and fine chemicals, catering to the needs of life science industry. It operates in three segments namely Manufacturing (CRAMS), that includes inte more

Websites CRP